Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 15/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | EED | O75530 | 3/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3890473 | 0.93 | EED (0.51) | SLC6A2SLC6A4SLC6A3CYP2D6HTR1A | |
| SCHEMBL7526768 | 0.91 | SLC6A4 (0.56) | SLC6A2SLC6A4SLC6A3CYP2D6HTR1A | |
| SCHEMBL1155798 | 0.85 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CYP2D6HTR1A | |
| SCHEMBL1155825 | 0.83 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3HTR1AEED | |
| SCHEMBL6925382 | 0.83 | SLC6A4 (0.48) | SLC6A2SLC6A4SLC6A3CYP2D6HTR1A | |
| SCHEMBL634531 | 0.82 | EED (0.48) | SLC6A2SLC6A4SLC6A3CYP2D6EED | |
| SCHEMBL6922676 | 0.81 | SLC6A4 (0.59) | SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL15259788 | 0.81 | FAAH (0.43) | SLC6A2SLC6A4SLC6A3CYP2D6EED | |
| SCHEMBL1155843 | 0.81 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3CYP2D6HTR1A | |
| SCHEMBL6923739 | 0.80 | SLC6A4 (0.50) | SLC6A2SLC6A4SLC6A3HTR1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933249-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933249-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2318362-B1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE INC (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130178509-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8242164-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242164-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110275694-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2318362-A2 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | Theravance, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
| US-7888386-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888386-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| WO-2010011811-A2 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178509-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | HTR6, SLC6A2, SLC6A4 | SLC6A2 2/4885SLC6A4 3/4885SLC6A3 4/4885 |
| US-20110275694-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | HTR6, SLC6A2, SLC6A4 | SLC6A2 2/4885SLC6A4 3/4885SLC6A3 4/4885 |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | HTR6, SLC6A2, SLC6A4 | SLC6A2 2/4885SLC6A4 3/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.